U.S. health department develops new Ebola treatment
The ASPR’s Biomedical Advanced Research and Development Authority (BARDA) has agreed to provide up to $38 million in support throughout the upcoming 23 months. These funds will be used in the development and production of the antibody therapeutic drug that will be used in studies.
The monoclonal antibodies can be used to bind to important proteins in the Ebola virus. Then the antibodies may neutralize the viral proteins, which would reduce the amount of Ebola that the immune system must combat.
“The world has experienced the worst Ebola epidemic in history; by rapidly developing therapeutics and vaccines with nimble technologies, we may save lives and bring future outbreaks under control more quickly,” BARDA Director Robin Robinson, Ph.D., said. “Regeneron’s technology facilitated the discovery and development of this monoclonal antibody therapeutic candidate in real time in just nine months as compared to the normal development cycle of several years, and the technology may have potential applications in future public health responses.”